Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06273943 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.

Study acronym: CABOPrEP
StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 23, 2024 (before its estimated October 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
The purpose of this study is to evaluate if offering long-acting injectable cabotegravir (CAB-LA) as an additional HIV prevention choice among oral PrEP-experienced men who have sex with men (MSM) in France can significantly increase the sustained PrEP use over time and the PrEP coverage of at-risk sexual risk behaviors.
Trial Details
NCT Number NCT06273943
Lead Sponsor ANRS, Emerging Infectious Diseases
Conditions
(from sponsor)		 Prevention
Enrollment 322 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov